Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence - Quiz - MDSpire

Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence

  • By

  • Shogo Baba

  • Mami Koketsu

  • Hajime Kuroda

  • Megumi Suzuki

  • Hiroshi Nishihara

  • Yasutaka Kato

  • Hiroyuki Kawami

  • Oi Harada

  • May 20, 2026

  • 0 min

Share

Original Source(s)

Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence

  • by Shogo Baba, Mami Koketsu, Hajime Kuroda, Megumi Suzuki, Hiroshi Nishihara, Yasutaka Kato, Hiroyuki Kawami, Oi Harada

  • May 20, 2026

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases